In the preclinical analysis included in the study, both MET tyrosine kinase inhibitor and an anti-MET monoclonal antibody inhibited the growth of a patient-derived colon cancer cell line harboring MET exon 14 deletion [28], thus suggesting its potential role as a predictive biomarker for MET inhibitors. Here, MET is linked to colonic neoplasm.